{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:32:43Z","timestamp":1794047563466,"version":"4.8.0"},"reference-count":0,"publisher":"Ferrata Storti Foundation (Haematologica)","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>This is the final \u226510-year report of a phase I\/II study and its extension study of second-line bosutinib for chronic phase chronic myeloid leukemia (CP-CML), representing the longest follow-up to date of any tyrosine kinase inhibitor after imatinib failure (n=284). Median (range) follow-up and treatment duration were 53.7 (0.5\u2013171.6) and 25.6 (0.2\u2013170.5) months, respectively. At the start of year 11, 19.4% of patients were receiving bosutinib; 13.4% were receiving bosutinib at study completion. The most common reasons for treatment discontinuation were lack of efficacy (disease progression\/unsatisfactory response; 26.8%) and adverse events (26.1%). Cumulative rates of complete cytogenetic response, major molecular response, and MR4 were 49.6%, 42.1%, and 37.1%, respectively. Kaplan\u2013Meier probabilities of maintaining response at year 11 were 58.3%, 56.1%, and 55.7%, respectively. At year 11, cumulative incidence of on-treatment disease progression\/death was 24.6%; 15 (5.3%) patients had ontreatment transformations to accelerated\/blast phase (one after year 5). The Kaplan\u2013Meier overall survival rate was 70.5%; 55 (19.4%) patients died on study (15 after year 5). At the start of year 11, 29\/55 (52.7%) patients still on bosutinib were receiving \u2265500 mg once daily. Thirteen patients had adverse events leading to discontinuation in year 6 or later. No new safety signals emerged. After \u226510 years, bosutinib demonstrated durable efficacy and acceptable safety as second-line treatment for CP-CML.<\/jats:p>","DOI":"10.3324\/haematol.2025.300221","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T07:42:27Z","timestamp":1781768547000},"source":"Crossref","is-referenced-by-count":0,"title":["Second-line bosutinib for chronic phase chronic myeloid leukemia after imatinib: final, 10-year results of a phase I\/II study"],"prefix":"10.3324","author":[{"given":"Carlo","family":"Gambacorti-Passerini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeow Tee","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iryna","family":"Dyagil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Pagnano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpad","family":"Batai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna G.","family":"Turkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Leip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Purcell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Viqueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2026,6,18]]},"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/14238\/80418","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/14238\/80418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:14:33Z","timestamp":1794046473000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/14238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":0,"URL":"https:\/\/doi.org\/10.3324\/haematol.2025.300221","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,18]]}}}